molecules-logo

Journal Browser

Journal Browser

Structural Analysis and Biological Evaluation of Compounds from Fungi—2nd Edition

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Natural Products Chemistry".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 2958

Special Issue Editors


E-Mail Website
Guest Editor
1. Engineering Research Center of Chinese Ministry of Education for Edible and Medicinal Fungi, Jilin Agricultural University, Changchun 130118, China
2. School of Life Sciences, Jilin University, Changchun 130012, China
Interests: fungi; natural compounds; pharmacological efficacy
Special Issues, Collections and Topics in MDPI journals
State Key Laboratory of Food Nutrition and Safety, College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China
Interests: fungi; functional compounds; structural analysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, increasing attention has been paid to the study of edible mushrooms that demonstrate medicinal functions. Mushrooms, such as Ganoderma sichuanense and Lentinula edodes, have been applied in clinical settings. However, although active compounds from mushrooms play a role in certain well-known signaling pathways involved in diseases, their mechanisms of action and target cells/molecules remain unclear.

The goal of this research topic is to identify compounds purified from mushrooms, explore their pharmacological properties, and clarify their mechanism of action and targets. Submitted manuscripts should adhere to the following requirements and scope:

1. The active compounds studied must be purified from mushrooms and subjected to explicit structural analysis. These compounds include, but are not limited to, polysaccharides, alkaloids, flavonoids, and various monomers. Please note that these compounds must have identified chemical structures.

2. The purified and structurally appraised compounds from mushrooms must demonstrate their pharmacological effects, which include, but are not limited to, immune-regulatory, anti-inflammatory, anti-neurodegenerative, anti-oxidative, and anti-tumor properties. Data obtained from in vitro experiments must be confirmed in animal models or preferably in clinical trials.

3. The study must clarify the mechanisms of action of the active compounds with a clear delineation of their targets, such as cells and cytokines associated with pharmacological properties.

Prof. Dr. Di Wang
Dr. Jia Song
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fungi
  • natural products
  • structure analysis
  • pharmacological properties
  • mechanism
  • disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 4619 KiB  
Article
Phenylspirodrimane with Moderate Reversal Effect of Multidrug Resistance Isolated from the Deep-Sea Fungus Stachybotrys sp. 3A00409
by Xinhua Ma, Min Wu, Zhenwei Chen, Fan Cao, Tianhua Zhong, Zhuhua Luo, Zongze Shao, Yonghong Zhang, Limin Chen and Zhiqiang Zhang
Molecules 2024, 29(7), 1685; https://doi.org/10.3390/molecules29071685 - 8 Apr 2024
Viewed by 984
Abstract
Two new phenylspirodrimanes, stachybotrins K and L (1 and 2), together with eight known analogues (310), were isolated from deep-sea-derived Stachybotrys sp. MCCC 3A00409. Their structures were determined by extensive NMR data and mass spectroscopic analysis. Absolute [...] Read more.
Two new phenylspirodrimanes, stachybotrins K and L (1 and 2), together with eight known analogues (310), were isolated from deep-sea-derived Stachybotrys sp. MCCC 3A00409. Their structures were determined by extensive NMR data and mass spectroscopic analysis. Absolute configurations of new compounds were determined through a comparison of their circular dichroism (CD) spectra with other reported compounds. The possible reversal effects of all compounds were assayed in the resistant cancer cell lines. Stachybotrysin B (8) can reverse multidrug resistance (MDR) in ABCB1-overexpression cells (KBv200, Hela/VCR) at the non-cytotoxic concentration. Doxorubicin accumulation assay and molecular-docking analysis reveal that the mechanism of its reversal MDR effect may be related to the increase in the intracellular concentration of substrate anticancer drugs. Full article
Show Figures

Graphical abstract

Review

Jump to: Research

30 pages, 7686 KiB  
Review
The Biological Activity of Ganoderma lucidum on Neurodegenerative Diseases: The Interplay between Different Active Compounds and the Pathological Hallmarks
by Wenhui Lian, Xu Yang, Qidong Duan, Jie Li, Yuting Zhao, Chunhui Yu, Tianzhu He, Tianxia Sun, Yu Zhao and Weinan Wang
Molecules 2024, 29(11), 2516; https://doi.org/10.3390/molecules29112516 - 26 May 2024
Viewed by 1517
Abstract
Neurodegenerative diseases represent a cluster of conditions characterized by the progressive degeneration of the structure and function of the nervous system. Despite significant advancements in understanding these diseases, therapeutic options remain limited. The medicinal mushroom Ganoderma lucidum has been recognized for its comprehensive [...] Read more.
Neurodegenerative diseases represent a cluster of conditions characterized by the progressive degeneration of the structure and function of the nervous system. Despite significant advancements in understanding these diseases, therapeutic options remain limited. The medicinal mushroom Ganoderma lucidum has been recognized for its comprehensive array of bioactive compounds with anti-inflammatory and antioxidative effects, which possess potential neuroprotective properties. This literature review collates and examines the existing research on the bioactivity of active compounds and extracts from Ganoderma lucidum in modulating the pathological hallmarks of neurodegenerative diseases. The structural information and preparation processes of specific components, such as individual ganoderic acids and unique fractions of polysaccharides, are presented in detail to facilitate structure–activity relationship research and scale up the investigation of in vivo pharmacology. The mechanisms of these components against neurodegenerative diseases are discussed on multiple levels and elaborately categorized in different patterns. It is clearly presented from the patterns that most polysaccharides of Ganoderma lucidum possess neurotrophic effects, while ganoderic acids preferentially target specific pathogenic proteins as well as regulating autophagy. Further clinical trials are necessary to assess the translational potential of these components in the development of novel multi-target drugs for neurodegenerative diseases. Full article
Show Figures

Graphical abstract

Back to TopTop